Moteur de recherche d’entreprises européennes
Financement de l’UE (9 999 817 €) : Établir des approches novatrices pour une prévention optimale des infections des bactéries résistantes dans les unités de soins intensifs néonatals en intégrant la … Hor26/02/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Établir des approches novatrices pour une prévention optimale des infections des bactéries résistantes dans les unités de soins intensifs néonatals en intégrant la recherche, la science de la mise en œuvre et la surveillance dans une plateforme mondiale durable.
Around 10% of newborns in Europe will be admitted to a neonatal intensive care unit (NICU). Critically ill babies are a highly vulnerable population for the acquisition of resistant bacteria. Sepsis is among the most common events in NICU and is known to be associated with high mortality and poor long-term outcomes. Despite rising awareness of high rates of resistant bacterial colonisation reported in NICU, there is very little robust specific data on globally applicable infection prevention and control (IPC) measures. NeoIPC focuses on new approaches to the prevention and management of resistant bacterial colonization and infection on NICU. The project builds on and further extends the collaboration between 13 partners with a proven track record in relevant areas, including neonatal infection, IPC, implementation science, microbiology and surveillance. NeoIPC aims to develop and implement an innovative approach towards the evaluation of IPC interventions combining a robust cost-efficient randomised trial combined with the evaluation of a suitable implementation science strategy and novel targeted clinical and genotypic surveillance. A further goal is to generate widely relevant pan-European network strategies to improve IPC in routine neonatal care. This will be achieved through six interrelated work packages to deliver a cluster randomised trial-implementation hybrid investigating the impact of optimised Kangaroo Care on infant hospital-acquired clinical sepsis and resistant bacterial colonisation, coupled with a comprehensive implementation strategy incorporating optimal targeted surveillance in a clinical network with tailored dissemination and exploitation to facilitate sustainable embedding of outputs. NeoIPC will generate globally transferrable outputs to reduce hospital transmission of resistant pathogens, foster and facilitate collaborative research and IPC implementation efforts with a broad and long-lasting impact for critically ill newborns and infants.
| Aristotelio Panepistimio Thessalonikis | 186 076 € |
| Asociacion Instituto de Investigacion Sanitaria Biobizkaia | 0,00 € |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 740 238 € |
| Fondazione Penta ETS | 2 919 511 € |
| SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT | 362 620 € |
| Servicio Vasco de Salud Osakidetza | 287 020 € |
| Stellenbosch University | 206 085 € |
| St George's Hospital Medical School | 1 262 241 € |
| STICHTING EUROPEAN CLINICAL RESEARCH ALLIANCE ON INFECTIOUS DISEASES | 553 503 € |
| TARTU ULIKOOL | 167 900 € |
| Universita Degli Studi Di Padova | 283 091 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 300 103 € |
| UNIVERSITAT BASEL | 455 983 € |
| UNIVERSITATS-KINDERSPITAL BEIDER BASEL | 0,00 € |
| UNIVERSITAT ZURICH | 724 466 € |
| Universiteit Antwerpen | 1 550 981 € |
https://cordis.europa.eu/project/id/965328
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
